首页(Home)
品牌专区(Brands-parters)
//自动完成提示
function beginSearch() {
if (document.getElementById("Keyword").value.replace(/(^\s*)|(\s*$)/g, "").length > 2) {
$("#divMsg").html("");
var tbSearch = document.getElementById("Keyword").value;
var div_msg = document.getElementById("divMsg");
div_msg.style.display = "block";
$.ajax({
type: "post",
dataType: "json", //数据格式:JSON
url: "/tools/submit_ajax.ashx?action=zhitishi",
data: { father: tbSearch },
async: false,
success: function (data) {
var str = "";
var str1 = "";
var str2 = "";
var str3 = "";
var SupplyType = data.SupplyType; //供应品类列表
var Brands = data.Brands; //品牌列表
var ProductStyle = data.ProductStyle; //产品列表
var str0 = "";
if (SupplyType != null && SupplyType != "") {
str0 += " Ignyta www.ignyta.com The company was originally launched in August 2011 by Jonathan E. Lim, M.D., former president, CEO, and board director of Halozyme Therapeutics, Inc., and Gary S. Firestein, M.D., director of the Clinical and Translational Research Institute, Dean and Associate Vice Chancellor of Translational Medicine, and Professor of Medicine at UC San Diego. In May 2013, Ignyta acquired Actagene Oncology, Inc., which had been co-founded by Patrick O’Connor, Ph.D., former CEO of Actagene and Global Research Therapeutic Area Head for Oncology at Pfizer.供应分类";
$.each(SupplyType, function () {//遍历Specification
str0 += "";
});
}
if (ProductStyle != null && ProductStyle != "") {
str1 += "产品分类";
$.each(ProductStyle, function () {//遍历ProductType
str1 += "";
});
}
if (Brands != null && Brands != "") {
str2 = "品牌";
$.each(Brands, function () {//遍历Brands
str2 += "";
});
}
str = str0 + str2 + "";
$("#divMsg").html(str);
}
});
}
else if (document.getElementById("Keyword").value.replace(/(^\s*)|(\s*$)/g, "").length == 0) {
var div_msg = document.getElementById("divMsg");
div_msg.style.display = "none";
div_msg.innerHTML = "";
}
}
自身免疫分子诊断公司
Ignyta, Inc., located in San Diego, California, is a trailblazing biotechnology company catalyzing personalized medicine with integrated Rx/Dx solutions for cancer and immunology. Our goal is to discover and develop revolutionary new drugs that target activated genes in cancer cells or reactivate the immune system for the customized treatment of cancer patients. We will achieve this goal by leveraging our proprietary cancer and immunology genomic and epigenomic knowledge bases to discover novel targets and deliver the next generation of targeted therapeutics accompanied by highly informative biomarkers for patient selection, treatment, and monitoring.
